Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
Marketers continue to leverage the power of mobile devices, but have learned it’s not all about the apps.
For years and years, pharmaceutical pricing has been under attack by consumers, professionals, and payers. More recently, the U.S. government has dramatically stepped up its assault, with price reduction proposals from Congress and stern words from President Trump indicating that drug pricing is a major ongoing focus of the administration. The 2018 timeline was dotted with government jabs at pharma pricing, as well as some attempts to take real action.
A sales rep preparing for her week isn’t thinking, What’s in my sales dashboard? What is my progress towards my call plan? She’s thinking, What are the burning issues in my territory this week? How should I adjust my plan based on the latest events and information that I have? Then she manually navigates her way through dashboards and reports to find these answers.
The market research company Gartner predicts that consumer demand for voice devices such as Amazon Echo and Google Home will generate $3.5 billion by 2021. These intelligent voice assistants, plus other digital technologies such as the Apple Watch, are slowly but steadily being adopted in healthcare.
Ogilvy Health recently asked some of its agency leaders – in creative, payer, digital, planning, and account – to share what they’re tracking in 2019.
In the era of precision medicine, life sciences companies are transforming customer engagement with complete, accurate and up-to-date customer data.
Most pharmaceutical brands are really happy with a handful of their agencies, satisfied with some, and not too thrilled with one or two. TGaS uncovered four areas to watch in 2019 through its benchmark-based consultancy.
Med Ad News asked its sources for the Agenda 2019 special feature which key questions for 2019 we’d left out. This is what they told us.
With Congressional hearings on drug prices, proposed rules for Medicare plans and new ICER efforts to link outcomes to value, finding answers on how to price and pay for drugs is still difficult.
With reports that the House Democratic leadership has agreed to hearings on Medicare for All, and a Harvard/Politico survey demonstrating that 84 percent of Democrats support a tax-funded national healthcare plan, the concept of Medicare for All is moving into the healthcare debate. At this point, however, Medicare for All is a concept defined by only general terms.